B.Riley sets Foghorn stock Buy rating, $10 target
The recent decline in Foghorn Therapeutics' stock was attributed to the discontinuation of another of its products, FHD-286. However, the analysts emphasized that this event does not impact their ...
Hosted on MSN8d
Bottom 100 Stocks to Buy: Is B. Riley Financial Uninvestable?
The markets were closed on Monday for Martin Luther King Jr. Day, which also marked the inauguration of Donald J. Trump, the ...
ClearPoint Neuro price target raised to $20 from $15 at B. Riley
B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $20 from $15 and keeps a Buy rating ...
B.Riley Financial Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)
In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...
B.Riley Financial Reaffirms Their Buy Rating on Altimmune (ALT)
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Altimmune (ALT – Research Report) yesterday and set a price target of ...
B. Riley upgrades Redwire on growth potential from Edge Autonomy acquisition
Learn about the latest financial trends and strategies in our comprehensive article written by a financial expert.
What is B. Riley’s Estimate for FormFactor FY2024 Earnings?
Research analysts at B. Riley increased their FY2024 earnings estimates for FormFactor in a research note issued on Monday, January 27th. B. Riley analyst C. Ellis now forecasts that the semiconductor ...
B. Riley Suspends Preferred Payouts Ahead of Note Redemption
B. Riley Financial Inc. suspended dividends on a pair of its preferred shares, holding off on cash payments to some investors ...